about
Dystrophin-deficient cardiomyocytes derived from human urine: new biologic reagents for drug discovery.Myofiber injury and regeneration in a canine homologue of Duchenne muscular dystrophy.Functional muscle analysis of the Tcap knockout mouse.Gene therapy prolongs survival and restores function in murine and canine models of myotubular myopathy.Ambulation training with and without partial weightbearing after traumatic brain injury: results of a randomized, controlled trial.The importance of electromyographic guidance and electrical stimulation for injection of botulinum toxin.Aging and physical mobility in group-housed Old World monkeysEnzyme replacement therapy rescues weakness and improves muscle pathology in mice with X-linked myotubular myopathy.Kinematics of gait in golden retriever muscular dystrophy.Canine models of Duchenne muscular dystrophy and their use in therapeutic strategies.Mesenchymal stem cells: emerging therapy for Duchenne muscular dystrophyDiaphragm remodeling and compensatory respiratory mechanics in a canine model of Duchenne muscular dystrophy.Golden retriever muscular dystrophy (GRMD): Developing and maintaining a colony and physiological functional measurements.Stem cell use in musculoskeletal disorders.The paradox of muscle hypertrophy in muscular dystrophy.Testosterone levels among men with spinal cord injury admitted to inpatient rehabilitation.Skinned single fibers from normal and dystrophin-deficient dogs incur comparable stretch-induced force deficits.Lumbar spinal moments in chronic back pain patients during supported lifting: a dynamic analysis.Low-dose cyclobenzaprine versus combination therapy with ibuprofen for acute neck or back pain with muscle spasm: a randomized trial.A single-dose resveratrol treatment in a mouse model of amyotrophic lateral sclerosis.Eccentric contraction injury in dystrophic canine muscle.Effects of prednisone in canine muscular dystrophy.Testosterone replacement therapy and motor function in men with spinal cord injury: a retrospective analysis.Dose-dependent response to intramuscular botulinum toxin type A for upper-limb spasticity in patients after a stroke.Selective serotonin reuptake inhibitor treatment of post-traumatic Klüver-Bucy syndrome.Obsessional disorders during recovery from severe head injury: report of four cases.The effects of normal ageing on neuropsychological functioning following traumatic brain injury.Assessment of neuroendocrine dysfunction following traumatic brain injury.Use of carbidopa-levodopa in a patient with hydrocephalus and frozen movement.Kinematic changes following botulinum toxin injection after traumatic brain injury.Comparison of two injection techniques using botulinum toxin in spastic hemiplegia.Evaluating motor end-plate-targeted injections of botulinum toxin type A in a canine modelRegulatory light chain phosphorylation increases eccentric contraction-induced injury in skinned fast-twitch fibersInhibitory casting decreases a vibratory inhibition index of the H-reflex in the spastic upper limbWeaning from mechanical ventilation in a general rehabilitation center: a commentaryContraction force generated by tarsal joint flexion and extension in dogs with golden retriever muscular dystrophyBotulinum toxin type A use in piriformis muscle syndrome: a pilot studyMyostatin expression in muscular dystrophies and mitochondrial encephalomyopathiesEffects of intra-articular botulinum toxin type A in an equine model of acute synovitis: a pilot studyEstablishing clinical end points of respiratory function in large animals for clinical translation
P50
Q30574663-FA89DAAF-761B-4FC3-9E11-7CB983D07959Q32122092-B5A008FD-C29B-46CD-9784-B471F45D1E98Q33832895-16843EEF-DC13-42D7-AB72-84CC9F2FE242Q33926944-10769308-E936-4A38-B7BB-C1A618C9A801Q34477050-BD7BA2CC-A6F4-4D73-8CC0-A22F88AB6058Q35568557-EB7B8992-EE0A-4549-AE76-99D351558D79Q36253156-BCCA6552-14B0-4848-B359-2B5AD015A34FQ36709135-9AE707AE-5C6A-49FB-815E-E825D88DDCCBQ37184680-E1B868A5-7383-4D4B-9E8B-4B029D1747E4Q37548291-4E0BC797-E983-46E4-9AD5-C33D39D20C39Q37560090-F28C7A5D-FFDC-4B66-908B-BB4B93E82BEDQ37679378-935C7FA0-4144-409A-A3C2-563240C444B5Q37824836-E394DF5E-32AA-4531-90A2-5F5B2BB6AFCDQ37894218-DA0CFCD5-3F52-4A95-88B3-A036772093CAQ37975319-A371A914-E000-4AA1-B9F8-ECAFF49A8D2CQ40304177-F4C8FB5F-F23B-4DC2-8D92-6D65F82E297DQ40442290-49404FCC-1F06-48C8-B529-F6A4BBFE67A0Q40882313-6DC283B3-3FBD-49F6-A734-22B9A5F00BBEQ42669572-43ED71E1-8D5D-4D89-B794-2E6EF66199D5Q42971929-6F653807-5DA9-48EE-B620-791B86E29642Q44209525-07C2DA4B-F4A4-4A37-BFB6-67E4D4061A81Q45093355-D8ABC1DD-4434-4D4A-85C0-91BE5A9211EBQ45422678-55EC76A3-B625-4B49-A3C0-0B1A31055125Q47228741-4C96D459-8DC8-482B-892D-BC8424395664Q48286895-2FE5A047-D56A-4BD4-8D97-27CAE4FC988EQ48435475-25FE8200-1095-401D-B63C-4061F57F8D3AQ48435504-B9DAB8B4-1905-4E8C-A170-1999F3DCCE14Q48441660-B38C7DFB-8582-456D-B0B0-46BD151E3C45Q48601677-73EB371F-E91E-4F83-9E01-F45207008602Q48791564-884217FA-4C64-42EC-97F4-5790815100B7Q48869499-838C7824-D3C8-43A1-85F1-3D57B9EA8542Q74509709-4E5EA510-9FEB-4FBB-B421-190A13115377Q75382928-E0B56F86-A860-41BD-89EC-91C8D9378AD9Q77909926-073CE281-E70A-4F46-B316-A79C4173B82BQ77921548-6138BA8E-E393-4332-9A3C-78FDFEAAAFB1Q78212609-63CA701E-F851-4AFC-AA4E-799255F53057Q78320805-19AB7B1F-F721-442D-BC54-AB81E7ADF072Q80332610-34BB57AC-3E2C-4974-9F8A-6C39773CF6DFQ80564601-7E6061F3-28C9-4DE1-AFA6-A86C2E4DA0B1Q83220084-BF659C33-B0FF-4CCC-A683-4225A7819663
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Martin K Childers
@nl
Martin K Childers
@sl
Martin K. Childers
@en
Martin K. Childers
@es
type
label
Martin K Childers
@nl
Martin K Childers
@sl
Martin K. Childers
@en
Martin K. Childers
@es
altLabel
Martin Childers
@en
prefLabel
Martin K Childers
@nl
Martin K Childers
@sl
Martin K. Childers
@en
Martin K. Childers
@es
P106
P1153
7007165507
P21
P31
P496
0000-0003-4754-0883